rethinkPeptides Search
Menu
Study breakdown

Itch (Pruritus) and Neuropeptides: How Substance P, CGRP, and Opioids Drive Itching

evidence
The takeaway

Neuropeptides (substance P, CGRP, endogenous opioids, NGF) play central roles in pruritus (itch) pathophysiology, with neuropeptide-targeted therapies offering new treatment approaches for chronic itching conditions.

Key finding

Neuropeptides (substance P, CGRP, endogenous opioids, NGF) play central roles in pruritus (itch) pathophysiology, with neuropeptide-targeted therapies

What the researchers found

Neuropeptides (substance P, CGRP, endogenous opioids, NGF) play central roles in pruritus (itch) pathophysiology, with neuropeptide-targeted therapies offering new treatment approaches for chronic itching conditions.

Why it matters

Relevant for peptide research.

How the study worked

research study.

What this study cannot tell us

See abstract.

How to read the evidence

emerging evidence.

When this study was published

Published in 2011.

The bigger picture

Advances peptide research.

Questions still open

  • Further research needed.

Common questions

What was studied?
Itch (Pruritus) and Neuropeptides: How Substance P, CGRP, and Opioids Drive Itching
What was found?
Neuropeptides (substance P, CGRP, endogenous opioids, NGF) play central roles in pruritus (itch) pathophysiology, with neuropeptide-targeted therapies offering new treatment approaches for chronic itching conditions.

Read the original research

Pruritus: an overview of current concepts.

Veterinary dermatology, 22(2), 121-31

Citation

Metz, Martin; Grundmann, Sonja; Ständer, Sonja. (2011). Pruritus: an overview of current concepts.. Veterinary dermatology, 22(2), 121-31. https://doi.org/10.1111/j.1365-3164.2010.00945.x